Contact Sensitization Potential of 828 Ointment
Condition: Healthy Volunteers
Intervention: HP828-101
Intervention description: Nine topical patch applications over 3 weeks, rest period of 2 weeks and challenge after 48 hours.
Phase: Phase 1
Study type: Interventional
Allocation: Non-Randomized
Intervention model: Single Group Assignment
Masking: Single (Outcomes Assessor)
Enrollment: 259.0
Sex: All
Minimum age: 18 Years
Maximum age: 65 Years
Healthy volunteers: Accepts Healthy Volunteers
Keywords: Contact sensitization; Healthy Adult Volunteers

Summary:

      Contact sensitization by patch applications.
    

Eligibility criteria:

        1. SUBJECTS 1.1 SUBJECT POPULATION

        Subjects will be normal, healthy volunteers of both genders aged 18 to 65 years.

        Inclusion Criteria:

        Subjects must satisfy all of the following criteria:

          1. Subjects must be ambulatory, 18 to 65 years of age and in reasonably good health (no
             physical required).

          2. Subjects may be of any race or skin type provided their skin pigmentation does not
             interfere with evaluations.

          3. Female subjects must be surgically sterile, post-menopausal or using an acceptable
             method of birth control.

          4. Minor deviations in normal medical history not considered to be clinically significant
             by the investigator and the sponsor will be permitted.

          5. Subjects must refrain from sunbathing, using tanning salons, swimming, or using hot
             tubs during the entire study.

          6. Bathing is permitted but subjects must agree to try and keep the patches as dry as
             possible.

          7. Subjects must read and sign the informed consent statement.

          8. All females of child bearing potential must agree to take an entry and exit urine
             pregnancy test

        Exclusion Criteria:

        Subjects with any of the following conditions are not eligible for participation:

          1. Any systemic disease or disorder, complicating factors or structural abnormality that
             would negatively affect the conduct or outcome of the study (i.e., hepatitis, acute or
             chronic renal insufficiency).

          2. Use of a prescribed pain medication, prescribed or over-the-counter anti-inflammatory
             drugs, immunosuppressive drugs or prescribed antihistamine medication (steroid nose
             drops and/or eye drops are permitted). Use of any over-the-counter pain medication
             that is ingested in quantities exceeding label instructions.

          3. Subjects who have received an investigational drug or have participated in a Draize
             type patch test within the past 28 days or who are currently participating in or plan
             to enter a clinical trial.

          4. A history of non-compliance or subjects who are considered potentially unreliable.

          5. A history of skin allergies, including known sensitivity or strong reactions to any
             cosmetics and/or personal care products, topically prepared medical dressings, tapes,
             or adhesives.

          6. A history of clinically significant skin diseases which may contraindicate
             participation, including psoriasis, active eczema (at the test sites), atopic
             dermatitis, and active cancer, even if currently controlled through medication.

          7. Current use of topical or oral antibiotics.

          8. Use of topical medications at the test area 2 weeks prior to enrollment or any body
             lotions/oils/creams at the test area for 48 hours prior to enrollment and throughout
             the trial.

          9. Female subjects who are pregnant, stop contraceptive measures, expect to become
             pregnant or who are breast-feeding.

         10. Subjects with any condition known to interfere with the absorption, distribution,
             metabolism, or excretion of drugs.

         11. Subjects with hematological disorders or immunologic disorders (HIV positive, AIDS,
             and Systemic Lupus Erythematosus).

         12. Subjects with any significant organ abnormality or disorders including gastric
             ulcer/insulin dependent diabetes.

         13. Subjects with any clinically significant illness (sought medical attention, fever,
             took prescription medication) within the 4 weeks prior to study entry.

         14. History of asthma, chronic bronchitis or any other bronchospastic condition that
             requires medication.

         15. Anticipated change in the use of a systemic medication during the study that may
             affect the conduct or outcome of the study. Subjects must be stabilized on these
             medications for a least one month prior to receiving study drug and continue same
             regimen throughout the study.

         16. Bilateral mastectomy for cancer involving removal of lymph nodes.

         17. Treatment of any type of cancer within the last six months.

         18. The Investigator may declare any subject ineligible for a sound medical reason.

         19. Subjects with allergies/known sensitivities to any of the ingredients of the test
             article.